STOCK TITAN

[8-K] GameSquare Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Clearside Biomedical, Inc. (CLSD) has issued a Definitive Proxy Statement (DEF 14A) for a Special Meeting on 29 Aug 2025. The Board is asking holders of the 78.5 m outstanding shares (record date: 28 Jul 2025) to approve a single corporate action:

  • Proposal 1 – Reverse Stock Split & Authorized Share Reduction: authorises the Board, at its discretion within 12 months, to combine shares in any ratio from 1-for-5 to 1-for-15 and simultaneously cut authorised common shares proportionately from the current 400 m down to 80 m–26.7 m, preserving par value ($0.001).

Rationale: CLSD has been out of compliance with Nasdaq’s $1.00 minimum bid price since 7 Feb 2025 and expects delisting notice after 6 Aug 2025. Management believes a higher share price following the reverse split is the most practical path to regain compliance and maintain Nasdaq Global Market listing, thereby protecting liquidity and financing options.

Voting mechanics: Proposal passes with a simple majority of votes cast; because it is deemed “routine” by NYSE rules, brokers may vote uninstructed street-name shares. No broker non-votes are expected. Quorum is >50% of outstanding shares (≥39.26 m). No dissenters’ rights apply.

Effects: Share counts, option pools and ATM capacity will shrink proportionally; fractional shares will be cashed out at the 5-day average market price. Ownership percentages and rights remain unchanged. The Board may abandon or defer the split if price compliance is regained independently.

Clearside Biomedical, Inc. (CLSD) ha pubblicato una Dichiarazione Definitiva di Procura (DEF 14A) per una Assemblea Straordinaria il 29 agosto 2025. Il Consiglio di Amministrazione chiede ai detentori delle 78,5 milioni di azioni in circolazione (data record: 28 luglio 2025) di approvare una singola azione societaria:

  • Proposta 1 – Raggruppamento Azionario e Riduzione delle Azioni Autorizzate: autorizza il Consiglio, a sua discrezione entro 12 mesi, a combinare le azioni in un rapporto da 1-azione ogni 5 a 1-azione ogni 15 e contemporaneamente ridurre proporzionalmente le azioni ordinarie autorizzate dall'attuale 400 milioni a un intervallo tra 80 milioni e 26,7 milioni, mantenendo il valore nominale ($0,001).

Motivazione: CLSD non rispetta il prezzo minimo di offerta di $1,00 richiesto da Nasdaq dal 7 febbraio 2025 e prevede una notifica di esclusione dopo il 6 agosto 2025. La direzione ritiene che un prezzo azionario più alto, conseguente al raggruppamento azionario, sia la soluzione più pratica per tornare in conformità e mantenere la quotazione al Nasdaq Global Market, proteggendo così liquidità e opzioni di finanziamento.

Meccanismi di voto: La proposta viene approvata con la maggioranza semplice dei voti espressi; poiché è considerata "routine" secondo le regole NYSE, i broker possono votare le azioni detenute in street name senza istruzioni. Non sono previsti voti non espressi dai broker. Il quorum è superiore al 50% delle azioni in circolazione (≥39,26 milioni). Non si applicano diritti di opposizione.

Effetti: Il numero di azioni, le riserve opzioni e la capacità ATM si ridurranno proporzionalmente; le azioni frazionarie saranno liquidate al prezzo medio di mercato a 5 giorni. Le percentuali di proprietà e i diritti rimangono invariati. Il Consiglio potrà abbandonare o posticipare il raggruppamento se il prezzo tornerà conforme autonomamente.

Clearside Biomedical, Inc. (CLSD) ha emitido una Declaración Definitiva de Poder (DEF 14A) para una Junta Especial el 29 de agosto de 2025. La Junta solicita a los titulares de las 78,5 millones de acciones en circulación (fecha de registro: 28 de julio de 2025) que aprueben una única acción corporativa:

  • Propuesta 1 – Consolidación de Acciones y Reducción de Acciones Autorizadas: autoriza a la Junta, a su discreción dentro de 12 meses, a combinar acciones en una proporción de 1 por 5 a 1 por 15 y simultáneamente reducir proporcionalmente las acciones comunes autorizadas desde las actuales 400 millones a un rango entre 80 millones y 26,7 millones, preservando el valor nominal ($0,001).

Justificación: CLSD no cumple con el precio mínimo de oferta de $1,00 requerido por Nasdaq desde el 7 de febrero de 2025 y espera una notificación de exclusión después del 6 de agosto de 2025. La dirección considera que un precio de acción más alto tras la consolidación es el camino más práctico para recuperar el cumplimiento y mantener la cotización en Nasdaq Global Market, protegiendo así la liquidez y las opciones de financiamiento.

Mecánica de votación: La propuesta se aprueba con mayoría simple de votos emitidos; dado que se considera "rutinaria" según las reglas de NYSE, los corredores pueden votar las acciones en nombre de sus clientes sin instrucciones. No se esperan votos no emitidos por los corredores. El quórum es superior al 50% de las acciones en circulación (≥39,26 millones). No se aplican derechos de disidencia.

Efectos: El número de acciones, las reservas de opciones y la capacidad ATM se reducirán proporcionalmente; las acciones fraccionarias se pagarán en efectivo al precio promedio del mercado de 5 días. Los porcentajes de propiedad y los derechos permanecen sin cambios. La Junta podrá abandonar o posponer la consolidación si el precio vuelve a cumplir por sí solo.

Clearside Biomedical, Inc. (CLSD)는 2025년 8월 29일 특별 주주총회를 위한 최종 위임장 보고서(DEF 14A)를 발행했습니다. 이사회는 7,850만 주의 발행 주식(기준일: 2025년 7월 28일) 보유자들에게 단일 회사 조치를 승인할 것을 요청하고 있습니다:

  • 제안 1 – 액면병합 및 승인 주식수 축소: 이사회가 재량에 따라 12개월 이내에 1주당 5주에서 1주당 15주까지의 비율로 주식을 병합하고 동시에 현재 4억 주에서 8천만 주에서 2,670만 주 사이로 승인된 보통주 수를 비례하여 줄이며 액면가($0.001)를 유지하도록 승인합니다.

배경: CLSD는 2025년 2월 7일부터 Nasdaq의 최소 입찰 가격 $1.00 요건을 충족하지 못해 2025년 8월 6일 이후 상장폐지 통지를 받을 것으로 예상됩니다. 경영진은 액면병합 후 주가 상승이 규정 준수를 회복하고 Nasdaq 글로벌 마켓 상장을 유지하는 가장 현실적인 방법이라고 판단하여 유동성과 자금 조달 옵션을 보호하고자 합니다.

투표 절차: 제안은 투표된 표의 단순 과반수로 통과됩니다; NYSE 규칙에 따라 '일상적'으로 간주되어 브로커들은 지시 없는 스트리트 네임 주식에 대해 투표할 수 있습니다. 브로커 미투표는 예상되지 않습니다. 정족수는 발행 주식의 50% 이상(≥3,926만 주)입니다. 반대 주주 권리는 적용되지 않습니다.

영향: 주식 수, 옵션 풀 및 ATM 용량이 비례하여 축소되며, 소수 주식은 5일 평균 시장 가격으로 현금화됩니다. 소유 비율과 권리는 변경되지 않습니다. 이사회는 가격이 독자적으로 규정 준수를 회복할 경우 병합을 취소하거나 연기할 수 있습니다.

Clearside Biomedical, Inc. (CLSD) a publié une Déclaration de Procuration Définitive (DEF 14A) pour une Réunion Spéciale le 29 août 2025. Le Conseil d'Administration demande aux détenteurs des 78,5 millions d’actions en circulation (date d’enregistrement : 28 juillet 2025) d’approuver une action unique de la société :

  • Proposition 1 – Regroupement d’Actions et Réduction des Actions Autorisées : autorise le Conseil à sa discrétion, dans les 12 mois, à regrouper les actions selon un ratio de 1 pour 5 à 1 pour 15 et à réduire simultanément le nombre d’actions ordinaires autorisées de 400 millions à une fourchette de 80 millions à 26,7 millions, en conservant la valeur nominale (0,001 $).

Justification : CLSD ne respecte pas le prix minimum d’offre de 1,00 $ requis par le Nasdaq depuis le 7 février 2025 et s’attend à recevoir un avis de radiation après le 6 août 2025. La direction estime qu’un prix de l’action plus élevé suite au regroupement est la solution la plus pratique pour retrouver la conformité et maintenir la cotation sur le Nasdaq Global Market, protégeant ainsi la liquidité et les options de financement.

Mécanique de vote : La proposition est adoptée à la majorité simple des votes exprimés ; considérée comme « routinière » selon les règles du NYSE, les courtiers peuvent voter les actions en nom propre sans instructions. Aucun vote non exprimé par les courtiers n’est attendu. Le quorum est supérieur à 50 % des actions en circulation (≥39,26 millions). Aucun droit de dissidence ne s’applique.

Effets : Le nombre d’actions, les pools d’options et la capacité ATM seront réduits proportionnellement ; les fractions d’actions seront rachetées au prix moyen du marché sur 5 jours. Les pourcentages de propriété et les droits restent inchangés. Le Conseil peut abandonner ou différer le regroupement si la conformité du prix est rétablie de manière autonome.

Clearside Biomedical, Inc. (CLSD) hat eine Endgültige Vollmachtsmitteilung (DEF 14A) für eine Sonderversammlung am 29. August 2025 herausgegeben. Der Vorstand bittet die Inhaber der 78,5 Millionen ausstehenden Aktien (Stichtag: 28. Juli 2025) um Zustimmung zu einer einzigen Unternehmensmaßnahme:

  • Vorschlag 1 – Aktiensplit nach unten & Reduzierung der genehmigten Aktien: Ermächtigt den Vorstand, innerhalb von 12 Monaten nach eigenem Ermessen Aktien im Verhältnis von 1:5 bis 1:15 zusammenzulegen und gleichzeitig die genehmigten Stammaktien proportional von derzeit 400 Mio. auf 80 Mio. bis 26,7 Mio. zu reduzieren, wobei der Nennwert ($0,001) erhalten bleibt.

Begründung: CLSD erfüllt seit dem 7. Februar 2025 nicht den Mindestgebotspreis von $1,00 der Nasdaq und erwartet nach dem 6. August 2025 eine Delisting-Benachrichtigung. Das Management ist der Ansicht, dass ein höherer Aktienkurs nach dem Reverse Split der praktischste Weg ist, um die Anforderungen wieder zu erfüllen und die Notierung am Nasdaq Global Market aufrechtzuerhalten, wodurch Liquidität und Finanzierungsmöglichkeiten geschützt werden.

Abstimmungsmodalitäten: Der Vorschlag wird mit einfacher Mehrheit der abgegebenen Stimmen angenommen; da er gemäß NYSE-Regeln als „routine“ gilt, können Broker unbeaufsichtigte Street-Name-Aktien abstimmen. Keine Broker-Non-Votes werden erwartet. Das Quorum liegt bei über 50 % der ausstehenden Aktien (≥39,26 Mio.). Keine Widerspruchsrechte gelten.

Auswirkungen: Aktienanzahl, Optionspools und ATM-Kapazität werden proportional reduziert; Bruchstücke werden zum 5-Tage-Durchschnittskurs ausgezahlt. Eigentumsanteile und Rechte bleiben unverändert. Der Vorstand kann den Split aufgeben oder verschieben, falls die Kursanforderungen eigenständig wieder erfüllt werden.

Positive
  • Maintains Nasdaq listing: Reverse split is the quickest route to regain the $1.00 bid price, protecting liquidity and institutional visibility.
  • Flexible ratio range (1-5 to 1-15) allows the Board to tailor the split to market conditions, increasing chance of compliance.
  • Authorized share cut alleviates concerns over excessive unissued shares post-split, limiting potential future dilution.
Negative
  • Liquidity risk: Fewer outstanding shares may widen spreads and reduce trading volume.
  • No guarantee of sustained price: Historical data show many reverse-split stocks drift back below compliance levels without operational improvements.
  • Odd-lot costs: Holders ending with <100 shares may face higher brokerage fees and selling difficulties.

Insights

TL;DR: Board seeks flexible 1-for-5–15 reverse split to avert Nasdaq delisting; modestly positive if it restores bid price, neutral otherwise.

The filing is defensive rather than transformative. A reverse split is a common cure for sub-$1 stocks; it neither improves fundamentals nor raises capital but preserves market access. Flexibility across 11 ratios lets the Board match prevailing prices and minimise post-split volatility. Because authorisation covers only 12 months and may be abandoned, dilution risk is limited to micro-rounding of fractional shares. The move could attract institutions barred from penny stocks and keep CLSD eligible for index inclusion, yet liquidity may fall as the float contracts and odd-lots rise. Success hinges on sustaining a >$1.00 price; history shows reverse splits often fade if unaccompanied by operating catalysts. Overall impact viewed as guardedly positive but not value-creating.

TL;DR: Proposal follows best-practice—single agenda item, proportional auth-share cut, routine vote; governance risks appear low.

The Board’s design addresses shareholder dilution concerns by pairing the split with an authorised share reduction, avoiding an inflated share reserve that could facilitate future issuances without approval. Voting thresholds are standard and broker discretion ensures likely passage. Cash-out for fractional shares is at a transparent 5-day VWAP, limiting dispute risk. Anti-takeover effects are acknowledged but minimal given reduced authorised pool. No insider entrenchment signals emerge; executives collectively own only 6.7 % pre-split. From a governance lens, the measure is procedurally sound and shareholder-friendly.

Clearside Biomedical, Inc. (CLSD) ha pubblicato una Dichiarazione Definitiva di Procura (DEF 14A) per una Assemblea Straordinaria il 29 agosto 2025. Il Consiglio di Amministrazione chiede ai detentori delle 78,5 milioni di azioni in circolazione (data record: 28 luglio 2025) di approvare una singola azione societaria:

  • Proposta 1 – Raggruppamento Azionario e Riduzione delle Azioni Autorizzate: autorizza il Consiglio, a sua discrezione entro 12 mesi, a combinare le azioni in un rapporto da 1-azione ogni 5 a 1-azione ogni 15 e contemporaneamente ridurre proporzionalmente le azioni ordinarie autorizzate dall'attuale 400 milioni a un intervallo tra 80 milioni e 26,7 milioni, mantenendo il valore nominale ($0,001).

Motivazione: CLSD non rispetta il prezzo minimo di offerta di $1,00 richiesto da Nasdaq dal 7 febbraio 2025 e prevede una notifica di esclusione dopo il 6 agosto 2025. La direzione ritiene che un prezzo azionario più alto, conseguente al raggruppamento azionario, sia la soluzione più pratica per tornare in conformità e mantenere la quotazione al Nasdaq Global Market, proteggendo così liquidità e opzioni di finanziamento.

Meccanismi di voto: La proposta viene approvata con la maggioranza semplice dei voti espressi; poiché è considerata "routine" secondo le regole NYSE, i broker possono votare le azioni detenute in street name senza istruzioni. Non sono previsti voti non espressi dai broker. Il quorum è superiore al 50% delle azioni in circolazione (≥39,26 milioni). Non si applicano diritti di opposizione.

Effetti: Il numero di azioni, le riserve opzioni e la capacità ATM si ridurranno proporzionalmente; le azioni frazionarie saranno liquidate al prezzo medio di mercato a 5 giorni. Le percentuali di proprietà e i diritti rimangono invariati. Il Consiglio potrà abbandonare o posticipare il raggruppamento se il prezzo tornerà conforme autonomamente.

Clearside Biomedical, Inc. (CLSD) ha emitido una Declaración Definitiva de Poder (DEF 14A) para una Junta Especial el 29 de agosto de 2025. La Junta solicita a los titulares de las 78,5 millones de acciones en circulación (fecha de registro: 28 de julio de 2025) que aprueben una única acción corporativa:

  • Propuesta 1 – Consolidación de Acciones y Reducción de Acciones Autorizadas: autoriza a la Junta, a su discreción dentro de 12 meses, a combinar acciones en una proporción de 1 por 5 a 1 por 15 y simultáneamente reducir proporcionalmente las acciones comunes autorizadas desde las actuales 400 millones a un rango entre 80 millones y 26,7 millones, preservando el valor nominal ($0,001).

Justificación: CLSD no cumple con el precio mínimo de oferta de $1,00 requerido por Nasdaq desde el 7 de febrero de 2025 y espera una notificación de exclusión después del 6 de agosto de 2025. La dirección considera que un precio de acción más alto tras la consolidación es el camino más práctico para recuperar el cumplimiento y mantener la cotización en Nasdaq Global Market, protegiendo así la liquidez y las opciones de financiamiento.

Mecánica de votación: La propuesta se aprueba con mayoría simple de votos emitidos; dado que se considera "rutinaria" según las reglas de NYSE, los corredores pueden votar las acciones en nombre de sus clientes sin instrucciones. No se esperan votos no emitidos por los corredores. El quórum es superior al 50% de las acciones en circulación (≥39,26 millones). No se aplican derechos de disidencia.

Efectos: El número de acciones, las reservas de opciones y la capacidad ATM se reducirán proporcionalmente; las acciones fraccionarias se pagarán en efectivo al precio promedio del mercado de 5 días. Los porcentajes de propiedad y los derechos permanecen sin cambios. La Junta podrá abandonar o posponer la consolidación si el precio vuelve a cumplir por sí solo.

Clearside Biomedical, Inc. (CLSD)는 2025년 8월 29일 특별 주주총회를 위한 최종 위임장 보고서(DEF 14A)를 발행했습니다. 이사회는 7,850만 주의 발행 주식(기준일: 2025년 7월 28일) 보유자들에게 단일 회사 조치를 승인할 것을 요청하고 있습니다:

  • 제안 1 – 액면병합 및 승인 주식수 축소: 이사회가 재량에 따라 12개월 이내에 1주당 5주에서 1주당 15주까지의 비율로 주식을 병합하고 동시에 현재 4억 주에서 8천만 주에서 2,670만 주 사이로 승인된 보통주 수를 비례하여 줄이며 액면가($0.001)를 유지하도록 승인합니다.

배경: CLSD는 2025년 2월 7일부터 Nasdaq의 최소 입찰 가격 $1.00 요건을 충족하지 못해 2025년 8월 6일 이후 상장폐지 통지를 받을 것으로 예상됩니다. 경영진은 액면병합 후 주가 상승이 규정 준수를 회복하고 Nasdaq 글로벌 마켓 상장을 유지하는 가장 현실적인 방법이라고 판단하여 유동성과 자금 조달 옵션을 보호하고자 합니다.

투표 절차: 제안은 투표된 표의 단순 과반수로 통과됩니다; NYSE 규칙에 따라 '일상적'으로 간주되어 브로커들은 지시 없는 스트리트 네임 주식에 대해 투표할 수 있습니다. 브로커 미투표는 예상되지 않습니다. 정족수는 발행 주식의 50% 이상(≥3,926만 주)입니다. 반대 주주 권리는 적용되지 않습니다.

영향: 주식 수, 옵션 풀 및 ATM 용량이 비례하여 축소되며, 소수 주식은 5일 평균 시장 가격으로 현금화됩니다. 소유 비율과 권리는 변경되지 않습니다. 이사회는 가격이 독자적으로 규정 준수를 회복할 경우 병합을 취소하거나 연기할 수 있습니다.

Clearside Biomedical, Inc. (CLSD) a publié une Déclaration de Procuration Définitive (DEF 14A) pour une Réunion Spéciale le 29 août 2025. Le Conseil d'Administration demande aux détenteurs des 78,5 millions d’actions en circulation (date d’enregistrement : 28 juillet 2025) d’approuver une action unique de la société :

  • Proposition 1 – Regroupement d’Actions et Réduction des Actions Autorisées : autorise le Conseil à sa discrétion, dans les 12 mois, à regrouper les actions selon un ratio de 1 pour 5 à 1 pour 15 et à réduire simultanément le nombre d’actions ordinaires autorisées de 400 millions à une fourchette de 80 millions à 26,7 millions, en conservant la valeur nominale (0,001 $).

Justification : CLSD ne respecte pas le prix minimum d’offre de 1,00 $ requis par le Nasdaq depuis le 7 février 2025 et s’attend à recevoir un avis de radiation après le 6 août 2025. La direction estime qu’un prix de l’action plus élevé suite au regroupement est la solution la plus pratique pour retrouver la conformité et maintenir la cotation sur le Nasdaq Global Market, protégeant ainsi la liquidité et les options de financement.

Mécanique de vote : La proposition est adoptée à la majorité simple des votes exprimés ; considérée comme « routinière » selon les règles du NYSE, les courtiers peuvent voter les actions en nom propre sans instructions. Aucun vote non exprimé par les courtiers n’est attendu. Le quorum est supérieur à 50 % des actions en circulation (≥39,26 millions). Aucun droit de dissidence ne s’applique.

Effets : Le nombre d’actions, les pools d’options et la capacité ATM seront réduits proportionnellement ; les fractions d’actions seront rachetées au prix moyen du marché sur 5 jours. Les pourcentages de propriété et les droits restent inchangés. Le Conseil peut abandonner ou différer le regroupement si la conformité du prix est rétablie de manière autonome.

Clearside Biomedical, Inc. (CLSD) hat eine Endgültige Vollmachtsmitteilung (DEF 14A) für eine Sonderversammlung am 29. August 2025 herausgegeben. Der Vorstand bittet die Inhaber der 78,5 Millionen ausstehenden Aktien (Stichtag: 28. Juli 2025) um Zustimmung zu einer einzigen Unternehmensmaßnahme:

  • Vorschlag 1 – Aktiensplit nach unten & Reduzierung der genehmigten Aktien: Ermächtigt den Vorstand, innerhalb von 12 Monaten nach eigenem Ermessen Aktien im Verhältnis von 1:5 bis 1:15 zusammenzulegen und gleichzeitig die genehmigten Stammaktien proportional von derzeit 400 Mio. auf 80 Mio. bis 26,7 Mio. zu reduzieren, wobei der Nennwert ($0,001) erhalten bleibt.

Begründung: CLSD erfüllt seit dem 7. Februar 2025 nicht den Mindestgebotspreis von $1,00 der Nasdaq und erwartet nach dem 6. August 2025 eine Delisting-Benachrichtigung. Das Management ist der Ansicht, dass ein höherer Aktienkurs nach dem Reverse Split der praktischste Weg ist, um die Anforderungen wieder zu erfüllen und die Notierung am Nasdaq Global Market aufrechtzuerhalten, wodurch Liquidität und Finanzierungsmöglichkeiten geschützt werden.

Abstimmungsmodalitäten: Der Vorschlag wird mit einfacher Mehrheit der abgegebenen Stimmen angenommen; da er gemäß NYSE-Regeln als „routine“ gilt, können Broker unbeaufsichtigte Street-Name-Aktien abstimmen. Keine Broker-Non-Votes werden erwartet. Das Quorum liegt bei über 50 % der ausstehenden Aktien (≥39,26 Mio.). Keine Widerspruchsrechte gelten.

Auswirkungen: Aktienanzahl, Optionspools und ATM-Kapazität werden proportional reduziert; Bruchstücke werden zum 5-Tage-Durchschnittskurs ausgezahlt. Eigentumsanteile und Rechte bleiben unverändert. Der Vorstand kann den Split aufgeben oder verschieben, falls die Kursanforderungen eigenständig wieder erfüllt werden.

false 0001714562 0001714562 2025-08-01 2025-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 1, 2025

 

 

 

GameSquare Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39389   99-1946435

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

6775 Cowboys Way, Ste. 1335

Frisco, Texas, USA

  75034
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (216) 464-6400

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   GAME   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

Repurchase Program

 

On August 4, 2025, GameSquare Holdings, Inc. (“GameSquare or the “Company”) issued a press release announcing the authorization of a share repurchase program, as described in greater detail in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished hereto as Exhibit 99.1.

 

Investor Relations Presentation

 

On August 4, 2025, GameSquare began utilizing a new investor relations presentation (the “Presentation”), which provides a performance summary of the Company for interested parties. A copy of the Presentation is furnished hereto as Exhibit 99.2.

 

Item 8.01. Other Events

 

On August 1, 2025, the Board of Directors (the “Board”) of the Company authorized a share repurchase program pursuant to which the Company may purchase shares of common stock, par value $0.0001 per share (the “Common Stock”) up to $5,000,000 worth of Common Stock. Under the repurchase program, GameSquare may purchase shares of its Common Stock on a discretionary basis from time to time through open market repurchases, in privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The timing and actual number of shares repurchased will be determined by management depending on a variety of factors, including, among other factors, stock price, trading volume, market conditions and other general business considerations. The repurchase program has no expiration date and may be modified, suspended, or terminated at any time. Repurchases under this program will be funded from the Company’s surplus cash and cash equivalents or future cash flow generated by its Ethereum yield strategy.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Share Repurchase Program Press Release issued by GameSquare Holdings, Inc., dated August 4, 2025.
99.2   Investor Relations Presentation issued by GameSquare Holdings, Inc., dated August 4, 2025.
104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GAMESQUARE HOLDINGS, INC.
  (Registrant)
     
Date: August 4, 2025 By: /s/ Justin Kenna
  Name: Justin Kenna
  Title: Chief Executive Officer and Director

 

 

 

FAQ

Why does CLSD want a reverse stock split?

To raise its share price above Nasdaq’s $1.00 minimum bid rule and avoid delisting, which could impair liquidity and financing.

What split ratios are being proposed for Clearside Biomedical (CLSD)?

The Board may select any ratio from 1-for-5 up to 1-for-15, executing one split within 12 months or not at all.

Will the number of authorised CLSD shares change?

Yes. Authorised common shares will drop proportionally from 400 m to between 80 m and 26.7 m, matching the chosen split ratio.

How will fractional shares be handled after the reverse split?

Fractional entitlements will be cashed out at the 5-day average closing price preceding the effective date; no fractional shares will be issued.

What vote is required for Proposal 1 to pass at the August 29, 2025 meeting?

A simple majority of votes cast is sufficient; brokers may vote uninstructed street-name shares because the item is deemed routine.

When is the record date for voting on the CLSD special meeting?

Shareholders of record as of 28 July 2025 are entitled to vote the 78,510,318 outstanding shares.
GAMESQUARE HLDGS INC

NASDAQ:GAME

GAME Rankings

GAME Latest News

GAME Latest SEC Filings

GAME Stock Data

80.25M
81.33M
14.29%
8.03%
2.98%
Electronic Gaming & Multimedia
Services-amusement & Recreation Services
Link
United States
FRISCO